Weight Research
Compounds studied in body weight reduction, adipose tissue loss, or obesity treatment.
5-Amino-1MQ
A synthetic small molecule studied as an inhibitor of NNMT, an enzyme implicated in obesity and metabolic dysregulation, with additional research in aged muscle regeneration.
View research notes →
AOD-9604
AOD-9604 is a synthetic fragment of human growth hormone studied for its lipolytic and antilipogenic properties. Unlike intact hGH, it does not bind the GH receptor, which means researchers can examine its fat-metabolism effects in isolation.
View research notes →
Cagrilintide
Cagrilintide is a long-acting amylin analog that has been studied extensively in combination with semaglutide. Here is what the Phase 3 data looks like.
View research notes →
Retatrutide
Retatrutide (LY3437943) is a triple hormone receptor agonist developed by Eli Lilly, simultaneously activating the GIP, GLP-1, and glucagon receptors. Phase 2 trials showed approximately 24% mean body weight reduction at 48 weeks, the largest reported for any obesity drug to date.
View research notes →
Semaglutide
Semaglutide has more large-scale human trial data behind it than almost any other peptide women research, and most of what's written about it still ignores the questions women actually ask: what it does to weight at midlife, what the PCOS research shows, and what a fair per-mg price looks like. Here is the evidence, the FDA picture, and the pricing, plainly.
View research notes →
Tirzepatide
Tirzepatide targets two incretin receptors at once, and in the trial record that has meant the largest weight reductions yet measured in a drug study, results that matter to the women comparing it against semaglutide for midlife metabolic research. Here is what the evidence actually shows, including the heart failure finding that is especially relevant to women.
View research notes →